Treatment response to Janus kinase inhibitor in a child affected by Aicardi‐Goutières syndrome

Treatment response to Janus kinase inhibitor in a child affected by Aicardi‐Goutières syndrome

Key Clinical Message Baricitinib, a Janus kinase inhibitor (JAK‐inhibitor), seems to contribute to an improvement of a child affected by Aicardi‐Goutières syndrome (AGS), reducing the interferon score and determining a recovery of cognitive, communicative, and relational dysfunctions, while the gros...

Full description

Bibliographic Details
Main Authors: Jessica Galli, Marco Cattalini, Erika Loi, Rosalba Monica Ferraro, Silvia Giliani, Simona Orcesi, Lorenzo Pinelli, Raffaele Badolato, Elisa Fazzi
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:Clinical Case Reports
Subjects:
Aicardi‐Goutières syndrome
baricitinib
JAK‐inhibitors
neurodevelopmental outcome
Online Access:https://doi.org/10.1002/ccr3.7724

Internet

https://doi.org/10.1002/ccr3.7724

Similar Items